Last reviewed · How we verify

Gabapentin/B-complex

Merck KGaA, Darmstadt, Germany · FDA-approved active Small molecule

Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, while B-complex vitamins support neuronal metabolism and myelin formation.

Gabapentin reduces neuronal excitability by binding to the alpha-2-delta subunit of voltage-gated calcium channels, while B-complex vitamins support neuronal metabolism and myelin formation. Used for Neuropathic pain (peripheral neuropathy, diabetic neuropathy), Postherpetic neuralgia, Adjunctive therapy for partial seizures.

At a glance

Generic nameGabapentin/B-complex
Also known asGavindo®
SponsorMerck KGaA, Darmstadt, Germany
Drug classAnticonvulsant/analgesic combination with vitamin supplementation
TargetAlpha-2-delta subunit of voltage-gated calcium channels (gabapentin component)
ModalitySmall molecule
Therapeutic areaNeurology; Pain Management
PhaseFDA-approved

Mechanism of action

Gabapentin is an anticonvulsant and analgesic that decreases calcium influx into neurons, reducing the release of excitatory neurotransmitters and thereby suppressing abnormal neuronal firing. The B-complex vitamins (typically B1, B6, B12) provide essential cofactors for nerve function, energy metabolism, and myelin synthesis, complementing gabapentin's mechanism to support peripheral nerve health and reduce neuropathic pain.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results